双功能反意义寡核酸中的改性核酸:探索它们的抗癌潜力
Natalia Bartyś1, Anna Pasternak1, Jolanta Lisowiec-Wąchnicka1
1Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704, Poznan, Poland.
ChemMedChem
|August 21, 2025
概括
具有特定化学修饰的双功能抗意义寡核酸 (BASO),如β-L-RNA和解锁核酸,通过调节基因拼接和减少癌细胞的增殖和运动来增强抗癌性质.
科学领域:
- 分子生物学
- 生物化学
- 癌症研究
背景情况:
- 双功能反意义寡核酸 (BASO) 是针对前传递 RNA 的拼接切换工具.
- 在癌症发展中,pyruvate kinase M1/2基因的替代拼接至关重要.
- 了解核酸修饰可以提高BASO的治疗效果.
研究的目的:
- 研究改性核酸对M1/2基因替代拼接的影响.
- 评估改性BASO在癌细胞中的抗癌潜力.
- 确定改善BASO治疗性能的化学修饰.
主要方法:
- 合成和应用各种修饰的BASO.
- 实时测量癌细胞的增殖和运动.
- 通过BASOs对替代拼接法规的分析.
主要成果:
- 特定的化学修改显著提高了BASO的治疗性能.
- 修改后的BASO减少了癌细胞的增殖,诱导了细胞死亡,并降低了细胞的运动能力.
- β-L-RNA和解锁核酸修饰显示出强大的拼接调节和抗癌作用.
结论:
- 化学修饰,特别是β-L-RNA和解锁核酸,提高了BASO在拼接调节和癌症治疗中的有效性.
- 这些修改为开发基于寡核酸的新型癌症治疗提供了有希望的策略.
- 该研究建议对蛋白质结合的寡核酸进行有效的修改,以提高治疗结果.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Mutagenicity and Carcinogenicity
1.4K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.4K
Combined Effects of Drugs: Synergism
4.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.7K


